

Development of a new Topoisomerase I inhibitor based on a Kamtotesin derivative that can be used as an ADC payload

PINOTBIO, INC



ONCOLOGY	Lead
Product Type	ADC (Antibody-Drug Conjugates) payload
Indication	Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Target	HGF, HER2, TROP2, EGFR
MoA(Mechanism of Action)	DNA Topoisomerase I inhibitor
Competitiveness	1) As an ABCG2 non-substrate, it can inhibit the drug efflux pump-mediated development of resistance 2) Suppresses the possibility of ILD due to minimizing non-selective uptake
Development Stage	Lead
Route of Administration	IV